CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2024-09-23
Cited: 0
Clicked: 1128
Hai ZOU, Mengyu ZHANG, Xue YANG, Huafeng SHOU, Zhenglin CHEN, Quanfeng ZHU, Ting LUO, Xiaozhou MOU, Xiaoyi CHEN. Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis[J]. Journal of Zhejiang University Science B, 2024, 25(9): 756-772.
@article{title="Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis",
author="Hai ZOU, Mengyu ZHANG, Xue YANG, Huafeng SHOU, Zhenglin CHEN, Quanfeng ZHU, Ting LUO, Xiaozhou MOU, Xiaoyi CHEN",
journal="Journal of Zhejiang University Science B",
volume="25",
number="9",
pages="756-772",
year="2024",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300691"
}
%0 Journal Article
%T Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis
%A Hai ZOU
%A Mengyu ZHANG
%A Xue YANG
%A Huafeng SHOU
%A Zhenglin CHEN
%A Quanfeng ZHU
%A Ting LUO
%A Xiaozhou MOU
%A Xiaoyi CHEN
%J Journal of Zhejiang University SCIENCE B
%V 25
%N 9
%P 756-772
%@ 1673-1581
%D 2024
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300691
TY - JOUR
T1 - Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis
A1 - Hai ZOU
A1 - Mengyu ZHANG
A1 - Xue YANG
A1 - Huafeng SHOU
A1 - Zhenglin CHEN
A1 - Quanfeng ZHU
A1 - Ting LUO
A1 - Xiaozhou MOU
A1 - Xiaoyi CHEN
J0 - Journal of Zhejiang University Science B
VL - 25
IS - 9
SP - 756
EP - 772
%@ 1673-1581
Y1 - 2024
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300691
Abstract: doxorubicin (DOX) is a commonly administered chemotherapy drug for treating hematological malignancies and solid tumors; however, its clinical application is limited by significant cardiotoxicity. cynaroside (Cyn) is a flavonoid glycoside distributed in honeysuckle, with confirmed potential biological functions in regulating inflammation, pyroptosis, and oxidative stress. Herein, the effects of Cyn were evaluated in a DOX-induced cardiotoxicity (DIC) mouse model, which was established by intraperitoneal injections of DOX (5 mg/kg) once a week for three weeks. The mice in the treatment group received dexrazoxane, MCC950, and Cyn every two days. Blood biochemistry, histopathology, immunohistochemistry, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blotting were conducted to investigate the cardioprotective effects and potential mechanisms of Cyn treatment. The results demonstrated the significant benefits of Cyn treatment in mitigating DIC; it could effectively alleviate oxidative stress to a certain extent, maintain the equilibrium of cell apoptosis, and enhance the cardiac function of mice. These effects were realized via regulating the transcription levels of pyroptosis-related genes, such as nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), caspase-1, and gasdermin D (GSDMD). Mechanistically, for DOX-induced myocardial injury, Cyn could significantly modulate the expression of pivotal genes, including adenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), sirtuin 3 (SIRT3), and nuclear factor erythroid 2-related factor 2 (Nrf2). We attribute it to the mediation of AMPK/SIRT3/Nrf2 pathway, which plays a central role in preventing DOX-induced cardiomyocyte injury. In conclusion, the present study confirms the therapeutic potential of Cyn in DIC by regulating the AMPK/SIRT3/Nrf2 pathway.
[1]AminFM, SharawyMH, AminMN, et al., 2023. Nifuroxazide mitigates doxorubicin-induced cardiovascular injury: insight into oxidative/NLRP3/GSDMD-mediated pyroptotic signaling modulation. Life Sci, 314:121311.
[2]BianHT, WangGH, HuangJJ, et al., 2020. Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat. J Neuroinflammation, 17(1):166.
[3]BouyahyaA, TahaD, BenaliT, et al., 2023. Natural sources, biological effects, and pharmacological properties of cynaroside. Biomed Pharmacother, 161:114337.
[4]ChenY, LiuYH, JiangK, et al., 2023. Linear ubiquitination of LKB1 activates AMPK pathway to inhibit NLRP3 inflammasome response and reduce chondrocyte pyroptosis in osteoarthritis. J Orthop Translat, 39:1-11.
[5]ChenZM, ZhongH, WeiJS, et al., 2019. Inhibition of Nrf2/HO-1 signaling leads to increased activation of the NLRP3 inflammasome in osteoarthritis. Arthritis Res Ther, 21:300.
[6]CollRC, HillJR, DayCJ, et al., 2019. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol, 15(6):556-559.
[7]CollRC, SchroderK, PelegrínP, 2022. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci, 43(8):653-668.
[8]FengJF, LiuZJ, ChenH, et al., 2021. Protective effect of cynaroside on sepsis-induced multiple organ injury through Nrf2/HO-1-dependent macrophage polarization. Eur J Pharmacol, 911:174522.
[9]FengJH, DongXW, YuHL, et al., 2021. Cynaroside protects the blue light-induced retinal degeneration through alleviating apoptosis and inducing autophagy in vitro and in vivo. Phytomedicine, 88:153604.
[10]FilomenaD, VersacciP, CiminoS, et al., 2020. Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines association. Int J Cardiol, 299:271-275.
[11]FuQ, LiJ, QiuLL, et al., 2020. Inhibiting NLRP3 inflammasome with MCC950 ameliorates perioperative neurocognitive disorders, suppressing neuroinflammation in the hippocampus in aged mice. Int Immunopharmacol, 82:106317.
[12]GroverSP, BharathiV, PosmaJJ, et al., 2023. Thrombin-mediated activation of PAR1 enhances doxorubicin-induced cardiac injury in mice. Blood Adv, 7(10):1945-1953.
[13]GuJW, HuangH, LiuCL, et al., 2021. Pinocembrin inhibited cardiomyocyte pyroptosis against doxorubicin-induced cardiac dysfunction via regulating Nrf2/Sirt3 signaling pathway. Int Immunopharmacol, 95:107533.
[14]GuoZ, TuoH, TangN, et al., 2022. Neuraminidase 1 deficiency attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice. Int J Biol Sci, 18(2):826-840.
[15]LeeSA, ParkBR, MoonSM, et al., 2020. Cynaroside protects human periodontal ligament cells from lipopolysaccharide-induced damage and inflammation through suppression of NF-κB activation. Arch Oral Biol, 120:104944.
[16]LiangQ, CaiWY, ZhaoYX, et al., 2020. Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. Pharmacol Res, 158:104884.
[17]LinYQ, LuoTY, WengAL, et al., 2020. Gallic acid alleviates gouty arthritis by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling. Front Immunol, 11:580593.
[18]LiuDW, ZhaoL, 2022. Spinacetin alleviates doxorubicin-induced cardiotoxicity by initiating protective autophagy through SIRT3/AMPK/mTOR pathways. Phytomedicine, 101:154098.
[19]MacedoAVS, HajjarLA, LyonAR, et al., 2019. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol, 1(1):68-79.
[20]ManganMSJ, OlhavaEJ, RoushWR, et al., 2018. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov, 17(8):588-606.
[21]MengLP, LinH, ZhangJ, et al., 2019. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. J Mol Cell Cardiol, 136:15-26.
[22]NaderiY, KhosravianiS, NasiriS, et al., 2023. Cardioprotective effects of minocycline against doxorubicin-induced cardiotoxicity. Biomed Pharmacother, 158:114055.
[23]PeiLH, LeYF, ChenH, et al., 2021. Cynaroside prevents macrophage polarization into pro-inflammatory phenotype and alleviates cecal ligation and puncture-induced liver injury by targeting PKM2/HIF-1α axis. Fitoterapia, 152:104922.
[24]RawatPS, JaiswalA, KhuranaA, et al., 2021. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother, 139:111708.
[25]SayedN, KhuranaA, GoduguC, 2019. Pharmaceutical perspective on the translational hurdles of phytoconstituents and strategies to overcome. J Drug Deliv Sci Technol, 53:101201.
[26]StammP, KirmesI, PalmerA, et al., 2021. Doxorubicin induces wide-spread transcriptional changes in the myocardium of hearts distinguishing between mice with preserved and impaired cardiac function. Life Sci, 284:119879.
[27]SunW, LiuCX, ChenQH, et al., 2018. SIRT3: a new regulator of cardiovascular diseases. Oxid Med Cell Longev, 2018:7293861.
[28]SunX, SunGB, WangM, et al., 2011. Protective effects of cynaroside against H2O2-induced apoptosis in H9c2 cardiomyoblasts. J Cell Biochem, 112(8):2019-2029.
[29]TanX, ZhangRY, LanMD, et al., 2023. Integration of transcriptomics, metabolomics, and lipidomics reveals the mechanisms of doxorubicin-induced inflammatory responses and myocardial dysfunction in mice. Biomed Pharmacother, 162:114733.
[30]WangDM, CaoLY, ZhouX, et al., 2022. Mitigation of honokiol on fluoride-induced mitochondrial oxidative stress, mitochondrial dysfunction, and cognitive deficits through activating AMPK/PGC-1α/Sirt3. J Hazard Mater, 437:129381.
[31]WangX, GaoYH, TianYH, et al., 2020. Integrative serum metabolomics and network analysis on mechanisms exploration of Ling-Gui-Zhu-Gan Decoction on doxorubicin-induced heart failure mice. J Ethnopharmacol, 250:112397.
[32]WangZR, YaoMR, JiangLY, et al., 2022. Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis. Biomed Pharmacother, 154:113572.
[33]WuJ, ZengZH, ZhangWJ, et al., 2019. Emerging role of SIRT3 in mitochondrial dysfunction and cardiovascular diseases. Free Radic Res, 53(2):139-149.
[34]XiaoL, DaiZW, TangWJ, et al., 2021. Astragaloside IV alleviates cerebral ischemia-reperfusion injury through NLRP3 inflammasome-mediated pyroptosis inhibition via activating Nrf2. Oxid Med Cell Longev, 2021:9925561.
[35]XiongX, LuLH, WangZY, et al., 2022. Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent mechanism. Biomed Pharmacother, 152:113199.
[36]YaoY, WangHH, YangY, et al., 2023. Dehydroepiandrosterone protects against oleic acid-triggered mitochondrial dysfunction to relieve oxidative stress and inflammation via activation of the AMPK-Nrf2 axis by targeting GPR30 in hepatocytes. Mol Immunol, 155:110-123.
[37]YinYL, NiuQQ, HouHY, et al., 2022. PAE ameliorates doxorubicin-induced cardiotoxicity via suppressing NHE1 phosphorylation and stimulating PI3K/AKT phosphorylation. Int Immunopharmacol, 113:109274.
[38]YuHL, LiJY, HuXL, et al., 2019. Protective effects of cynaroside on oxidative stress in retinal pigment epithelial cells. J Biochem Mol Toxicol, 33(8):e22352.
[39]YuP, ZhangX, LiuN, et al., 2021. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther, 6:128.
[40]YuXX, RuanY, HuangXQ, et al., 2020. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem Biophys Res Commun, 523(1):140-146.
[41]YuanCY, WuZ, JinCL, et al., 2023. Qiangxin recipe improves doxorubicin-induced chronic heart failure by enhancing KLF5-mediated glucose metabolism. Phytomedicine, 112:154697.
[42]ZengC, 2020. NLRP3 inflammasomes-mediated pyroptosis contributes to dilated cardiomyopathy and doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol, 140(Suppl):22.
[43]ZengZL, LiGH, WuSY, et al., 2019. Role of pyroptosis in cardiovascular disease. Cell Prolif, 52(2):e12563.
[44]ZhangCY, ZhaoM, WangBW, et al., 2021. The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson’s disease. Redox Biol, 47:102134.
[45]ZhangL, JiangYH, FanCD, et al., 2021. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother, 143:112133.
[46]ZhangYP, NiL, LinBW, et al., 2021. SNX17 protects the heart from doxorubicin-induced cardiotoxicity by modulating LMOD2 degradation. Pharmacol Res, 169:105642.
Open peer comments: Debate/Discuss/Question/Opinion
<1>